Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539
| العنوان: | Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539 |
|---|---|
| المؤلفون: | C Leland Rogers, Stephanie L Pugh, Michael A Vogelbaum, Arie Perry, Lynn S Ashby, Jignesh M Modi, Anthony M Alleman, Igor J Barani, Steve Braunstein, Joseph A Bovi, John F de Groot, Anthony C Whitton, Scott M Lindhorst, Nimisha Deb, Dennis C Shrieve, Hui-Kuo Shu, Beatrice Bloom, Mitchell Machtay, Mark V Mishra, Clifford G Robinson, Minhee Won, Minesh P Mehta |
| المصدر: | Neuro Oncol |
| بيانات النشر: | Oxford University Press (OUP), 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Cancer Research, Oncology, Clinical Investigations, Neurology (clinical) |
| الوصف: | Background Three- and five-year progression-free survival (PFS) for low-risk meningioma managed with surgery and observation reportedly exceeds 90%. Herewith we summarize outcomes for low-risk meningioma patients enrolled on NRG/RTOG 0539. Methods This phase II trial allocated patients to one of three groups per World Health Organization grade, recurrence status, and resection extent. Low-risk patients had either gross total (GTR) or subtotal resection (STR) for a newly diagnosed grade 1 meningioma and were observed after surgery. The primary endpoint was 3-year PFS. Adverse events (AEs) were scored using Common Terminology Criteria for Adverse Events (CTCAE) version 3. Results Among 60 evaluable patients, the median follow-up was 9.1 years. The 3-, 5-, and 10-year rates were 91.4% (95% CI, 84.2 to 98.6), 89.4% (95% CI, 81.3 to 97.5), 85.0% (95% CI, 75.3 to 94.7) for PFS and 98.3% (95% CI, 94.9 to 100), 98.3%, (95% CI, 94.9 to 100), 93.8% (95% CI, 87.0 to 100) for overall survival (OS), respectively. With centrally confirmed GTR, 3/5/10y PFS and OS rates were 94.3/94.3/87.6% and 97.1/97.1/90.4%. With STR, 3/5/10y PFS rates were 83.1/72.7/72.7% and 10y OS 100%. Five patients reported one grade 3, four grade 2, and five grade 1 AEs. There were no grade 4 or 5 AEs. Conclusions These results prospectively validate high PFS and OS for low-risk meningioma managed surgically but raise questions regarding optimal management following STR, a subcohort that could potentially benefit from adjuvant therapy. |
| تدمد: | 1523-5866 1522-8517 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8161b7868dbcbe958fd6287e314bf9bb https://doi.org/10.1093/neuonc/noac137 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....8161b7868dbcbe958fd6287e314bf9bb |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15235866 15228517 |
|---|